Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6837 Monotherapy and Combination Therapy in Advanced/Metastatic Solid Tumors
NCT06460961Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of MK-6837 in solid tumor (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 35 months and 1 more. Started Jul 2024; status: completed.
02
Drugs
MK-6837
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06460961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06460961.